EGFR and breast cancer: Stamm Hauke et al. showed blocking TIGIT or PVR resulted in enhanced immune cell-mediated lysis of BC cell lines (SKBR-3, MDA-MB-231, MDA-MB-468, and BT549) and additionally increased the cytotoxic effects of a bispecific T cell engager BiTE® antibody construct targeting EGFR [18].